Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial
J. Clin. Oncol 2022 Jul 22;[EPub Ahead of Print], LM Fornecker, J Lazarovici, I Aurer, RO Casasnovas, AC Gac, C Bonnet, K Bouabdallah, P Feugier, L Specht, L Molina, M Touati, C Borel, A Stamatoullas, E Nicolas-Virelizier, L Pascal, P Lugtenburg, N Di Renzo, T Vander Borght, A Traverse-Glehen, P Dartigues, M Hutchings, A Versari, M Meignan, M Federico, M AndréFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.